<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01646437</url>
  </required_header>
  <id_info>
    <org_study_id>TIPS-3</org_study_id>
    <nct_id>NCT01646437</nct_id>
  </id_info>
  <brief_title>The International Polycap Study 3 (TIPS-3)</brief_title>
  <acronym>TIPS-3</acronym>
  <official_title>The International Polycap Study 3 (TIPS-3) is a Randomized Double-blind Placebo-controlled Trial for the Evaluation of a Polycap, Low Dose Aspirin and Vitamin D Supplementation in Primary Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cadila Pharnmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Stroke Foundation of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized 2x2x2 factorial design placebo controlled trial will enroll 5000 participants&#xD;
      (women 60 years or older and men 55 years or older) without known heart disease or prior&#xD;
      stroke and without a clear indication or contraindication to any of the study medications.&#xD;
      Eligible and consenting individuals will be randomized to receive either the active study&#xD;
      medications or placebo (dummy pills) and will be monitored for an average of 5 years. The&#xD;
      study will include people from at 10 countries, will be conducted by an international group&#xD;
      of scientists and physicians and will be coordinated by the Population Health Research&#xD;
      Institute at Hamilton Health Sciences.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD), cancers and osteoporosis collectively make up the largest&#xD;
      disease burden globally. CVD is the major cause of death and disability and affects about&#xD;
      half of the population over their lifetimes. Cancers are a leading cause of death and it&#xD;
      accounts for 13.0% of all deaths. The commonest forms include lung, breast, prostate,&#xD;
      colorectum, stomach and liver cancer. It is estimated that over 200 hundred million people&#xD;
      worldwide are living with osteoporosis. This is the underlying pathologic predisposition to&#xD;
      fractures of the hip, vertebral body, and distal forearm. CVD, cancers and osteoporotic&#xD;
      fractures increase with age and so their burden is expected to substantially increase over&#xD;
      the next few decades. Simple, safe and effective preventive strategies which can reduce the&#xD;
      incidence and prevalence of these 3 diseases are therefore urgently needed&#xD;
&#xD;
      It is suggested that this polypill could be given to all individuals with a CVD event as well&#xD;
      as to anyone over 55 years (primary prevention) without the need for any measurement of risk&#xD;
      factors. The polypill contains 3 blood pressure lowing medications and a statin in a single&#xD;
      tablet. This includes hydrochlorothiazide (25 mg), atenolol (100 mg), ramipril (10 mg) and&#xD;
      simvastatin (40 mg). In addition, to the polypill (Polycap), participants will be randomized&#xD;
      to receive aspirin (75mg) and vitamin D (60,000 IU monthly). This factorial design on 3&#xD;
      distinct treatment arms which could reduce CVD, fractures and cancers could have large&#xD;
      implications for the prevention of several of the important chronic diseases in middle and&#xD;
      old age, using safe and inexpensive medications/supplements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polycap Primary Objective</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether the Polycap reduces the risk of the composite outcome of CVD events which includes major CVD (CV death, non-fatal stroke, non-fatal MI), plus heart failure, resuscitated cardiac arrest, or arterial revascularization compared to placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspirin Primary Objective</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether aspirin reduces the risk of composite outcome of major CV events (CV death, non-fatal MI or non-fatal stroke,) compared to its placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin D Primary Objective</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether vitamin D reduces the risk of fractures compared to its placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined Effects of Polycap and Aspirin on CVD Events</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine the combined effect of aspirin and the Polycap (i.e. double treatment) on major CV events (CV death, non-fatal MI or non-fatal stroke), heart failure, resuscitated cardiac arrest, or arterial revascularization compared to double-placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polycap Secondary Objective</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether the Polycap reduces the risk of the composite of CV death, non-fatal stroke, and non-fatal MI compared to its placebo.To determine whether the Polycap reduces the risk of the composite outcome of major CVD (CV death, non- fatal stroke, non-fatal myocardial infarction [MI]), heart failure, resuscitated cardiac arrest, arterial revascularization, or angina with evidence of ischemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspirin Secondary Objective</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether a daily aspirin reduces the risk of the composite outcome of major CV events (CV death, non-fatal MI or non-fatal stroke) and cancers compared to its placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Secondary Objective</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether vitamin D reduces the risk of the composite outcome of CV events, fractures and cancers, and the risk of falls compared to its placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Effects of Polycap and Aspirin on CVD Events Secondary Outcome A</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether the Polycap and aspirin reduces the risk of the composite of CV death, non-fatal stroke, and non-fatal MI compared to double placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Effects of Polycap and Aspirin on CVD Events Secondary Outcome B</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether the Polycap and aspirin reduces the risk of the composite outcome of major CVD (CV death, non- fatal stroke, non-fatal myocardial infarction [MI]), heart failure, resuscitated cardiac arrest, arterial revascularization, or angina with evidence of ischemia, compared to double-placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total mortality</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To assess the effect of each of the 3 treatments on total mortality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incident and recurrent CV events</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To determine whether the Polycap reduces the risk of incident and recurrent CV events (which is comprised of major CVD (CV death, non- fatal stroke, non-fatal myocardial infarction [MI]), plus heart failure, resuscitated cardiac arrest or arterial revascularization)).</description>
  </other_outcome>
  <other_outcome>
    <measure>Long term safety</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To assess the long-term safety of each treatment (Polycap, Aspirin or Vitamin D) versus their respective placebo on safety and tolerability.</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To assess the effect of the Polycap and Aspirin on visual acuity change from baseline and onset of age-related macular degeneration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To assess the effect of each of the 3 treatments on cognitive function</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economics</measure>
    <time_frame>Participants will be followed for an average of 4.25 years</time_frame>
    <description>To assess the economic impact of the Polycap</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7793</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Fractures</condition>
  <condition>Cancers</condition>
  <arm_group>
    <arm_group_label>Polycap vs. matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polycap is a once daily capsule containing thiazide (25mg), atenolol (100mg), ramipril (10mg) and simvastatin (40mg) vs. matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin vs. matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 75mg tablet of Aspirin vs. matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D vs. matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly oral dosage of 60,000IU vs. matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polycap</intervention_name>
    <description>Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily</description>
    <arm_group_label>Polycap vs. matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>75 mg daily</description>
    <arm_group_label>Aspirin vs. matching placebo</arm_group_label>
    <other_name>enteric coated aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>60,000 IU monthly</description>
    <arm_group_label>Vitamin D vs. matching placebo</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Aspirin vs. matching placebo</arm_group_label>
    <arm_group_label>Polycap vs. matching placebo</arm_group_label>
    <arm_group_label>Vitamin D vs. matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged ≥ 50 years and women aged ≥ 55 years with an INTERHEART risk score ≥ 10 OR&#xD;
             men and women aged ≥ 65 years with an INTERHEART risk score of ≥5.&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Participants with a clear clinical indication, contraindication, preference for or&#xD;
             intolerance to statin, beta blocker (e.g. bradycardia), ACE inhibitor, diuretic,&#xD;
             aspirin or clopidogrel in the judgment of the physician.&#xD;
&#xD;
          -  Regular use of vitamin D at doses higher than 400 IU per day.&#xD;
&#xD;
          -  Hypercalcemia, hyperparathyroidism, osteomalacia or other contraindication or&#xD;
             indication for vitamin D therapy.&#xD;
&#xD;
          -  Peptic ulcer disease, frequent dyspepsia or bleeding.&#xD;
&#xD;
          -  Expected long term use of anticoagulants&#xD;
&#xD;
          -  Known vascular disease. (e.g., Stroke, TIA, Angina, MI, ACS, PVD including&#xD;
             claudication and amputation).&#xD;
&#xD;
          -  Mean systolic BP (using 2 automatic readings) below 120 mm Hg at run-in.&#xD;
&#xD;
          -  Symptomatic hypotension (e.g., dizziness with SBP &lt;110 mm Hg systolic) during the&#xD;
             run-in phase.&#xD;
&#xD;
          -  Chronic liver disease or abnormal liver function, i.e. ALT or AST &gt; 3 x ULN.&#xD;
&#xD;
          -  Inflammatory muscle disease (such as dermatomyositis or polymyositis) or creatine&#xD;
             kinase (CK) &gt; 3 x ULN.&#xD;
&#xD;
          -  Severe renal impairment (serum creatinine &gt;264 µmol/L).&#xD;
&#xD;
          -  History of malignancy affecting any organ system, except basal cell carcinoma of the&#xD;
             skin, within the previous 5 years.&#xD;
&#xD;
          -  Other serious condition(s) likely to interfere with study participation or with the&#xD;
             ability to complete the trial.&#xD;
&#xD;
          -  Concurrent use of any experimental pharmacological agent.&#xD;
&#xD;
          -  Inability to attend follow-up as required by the protocol for at least 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salim Yusuf</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prem Pais</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. John's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eminence</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundaction Oftamologica De Santander (FOSCAL)</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harapan Kita Hopsital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiti Teknologi MARA (UiTM)</name>
      <address>
        <city>Shah Alam</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult Medicine &amp; Medical Research Unit, Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamoja Tunaweza Women's Centre</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fattouma Bourguiba University Hospital</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Tanzania</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>Salim Yusuf's office</investigator_full_name>
    <investigator_title>Executive Director - Population Health Research Institute, Professor of Medicine - McMaster University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

